Publication

March 6, 2026 Publication

BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial

AUTHORS Gordon et al
Programs Zavabresib (OPN-2853)

https://link.springer.com/article/10.1007/s00280-026-04871-3?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=nonoa_20260306&utm_content=10.1007%2Fs00280-026-04871-3

March 2, 2026 Publication

BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD

AUTHORS Kumar et al
Programs OPN-51107

https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2025031983/566894/BET-inhibition-blunts-antibody-production-and?redirectedFrom=fulltext

November 5, 2025 Publication

Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma models

AUTHORS Ott, et al
Programs OPN-TEAD

https://www.nature.com/articles/s41467-025-64682-7

October 5, 2023 Publication

Phase IIa Study of PLX2853 in Gynecologic Cancers with known ARID1A mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-resistant epithelial ovarian cancer

AUTHORS Duska, et al
Programs Zavabresib (OPN-2853)

https://ascopubs.org/doi/abs/10.1200/PO.23.00235

May 31, 2022 Publication

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

AUTHORS Kim, et al
Programs OPN-51107

https://doi.org/10.1016/j.leukres.2022.106884

October 15, 2021 Publication

Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft- Versus-Host Disease

AUTHORS Snyder, et al
Programs OPN-51107, Zavabresib (OPN-2853)

https://doi.org/10.3389/fonc.2021.760789

January 28, 2021 Publication

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia

AUTHORS Lee, et al
Programs OPN-51107

https://doi.org/10.3324/haematol.2020.247346

July 28, 2020 Publication

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression

AUTHORS Cummin, et al
Programs OPN-51107, Zavabresib (OPN-2853)

https://doi.org/10.1182/bloodadvances.2020002231

January 14, 2020 Publication

Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma

AUTHORS Tiago, et al
Programs OPN-51107

https://doi.org/10.1038/s41416-019-0724-y

November 6, 2019 Publication

PLX3397 inhibits the accumulation of intra-tumoral macrophages and improves bromodomain and extra-terminal inhibitor efficacy in melanoma

AUTHORS Erkes, et al
Programs OPN-51107

https://doi.org/10.1111/pcmr.12845

1 2 3 next